References
- Keam SJ. Doripenem: a review of its use in the treatment of bacterial infections. Drugs. 2008;68:2021–57.
- Yoshida I, Fujimura T, Jinushi Y, Higashiyama I, Sugimori G, Yamano Y. Anitimicrobial susceptibility of clinical isolates of aerobic Gram negative bacteria in 2002. Jpn J Chemother. 2006;54:355–77.
- Yamada Y, Ikawa K, Nakamura K, Mitsui K, Narushima M, Hibi H, et al.. Penetration of doripenem into prostatic tissue following intravenous administration in prostatectomy patients. Int J Antimicrob Agents. 2010;35(5):504–6.
- Greer ND. Doripenem (Doribax): the newest addition to the carbapenems. Proceedings (Bayl Univ Med Cent). 2008;21:337–41.
- Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al.. Comparative review of the carbapenems. Drugs. 2007;67(7):1027–52.
- Matthews SJ, Lancaster JW. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clin Ther. 2009;31:42–63.
- Ikeda K, Ikawa K, Morikawa N, Kameda K, Urakawa N, Ohge H, et al.. Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;867(1):20–5.
- Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn. 1981;4(11):879–85.
- Drusano GL, Preston SL, Van Guilder M, North D, Gombert M, Oefelein M, et al.. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother. 2000;44:2046–51.
- Shionogi & Co. Ltd. Finibax® prescribing information (interview form). February 2008 version. Osaka: Shionogi & Co. Ltd ; 2008.
- Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22:89–96.
- Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–12.
- Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;36 Suppl 1: S42–50.
- Wagenlehner FM, Weidner W, Sörgel F, Naber KG. The role of antibiotics in chronic bacterial prostatitis. Int J Antimicrob Agents. 2005;26(1):1–7.
- Ikawa K, Morikawa N, Urakawa N, Ikeda K, Ohge H, Sueda T. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J Antimicrob Chemother. 2007;60:1395–7.
- The European Committee on Antimicrobial Susceptibility Testing (EUCAST). http://www.eucast.org/mic_distributions/.
- Mori H, Nakamoto T, Momoki S, Kato S, Kishiro I, Nagatani T, et al.. Clinical analysis and penetration of the bronchoalveolar area with panipenem/betamipron (PAPM/BP) in patients with chronic bronchitis. Respir Res. 1998;17(1):71–7.